Clinical trials: Thyroid-Associated Ophthalmopathy
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen
Thyroid Associated Ophthalmopathy
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
The purpose of this study is to determine whether periorbital injection of glucocorticoid is effective and necessary in the treatment of mild TAO.
- Trial name
- NCT04548284
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease, Thyroid Eye Disease, TED
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).
- Conditions
- Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid Eye Disease (TED)
- Trial name
- NCT07308964
- Testing
- Teprotumumab Injection [Tepezza]
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Thyroid Eye Disease, TED
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease
- Trial name
- NCT06126783
- Testing
- IBI311
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid-associated Ophthalmopathy
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
Thyroid-associated ophthalmopathy (TAO) is an autoimmune process that can affect the orbital and periorbital tissues and the thyroid gland.
- Trial name
- NCT01599273
- Testing
- subconjunctival triamcinolone injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Dysthyroid Orbitopathy
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
The purpose of this protocol is to study orbital structures in Graves´ Disease using multidetector computed tomography and color doppler imaging.
- Trial name
- NCT00665795
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
Graves´ Disease, Thyroid Associated Ophthalmopathy
Rituximab in the Treatment of Graves' Disease
Aim: In a phase II pilot study encompassing 20 patients with Graves' disease to evaluate the effect of rituximab: 1. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies…
- Trial name
- NCT00150111
- Testing
- Methimazole, Rituximab, Immunization with various vaccines
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Thyroid Eye Disease (TED)
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
- Trial name
- NCT07211776
- Testing
- ZL-1109 (VRDN-003)
- Where
- 26 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Thyroid Eye Disease, Graves Ophthalmopathy
Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease
The trial tests the hypothesis that, in adults with active, moderate-to-severe Graves' orbitopathy, 24 weeks of oral atorvastatin 20 mg daily added to a standard 12-week course of intravenous methylprednisolone produces a greater…
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- SEMAR-TED (NCT07762105)
- Testing
- Atorvastatin, methylprednisolone (IVMP)
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Banu Aji Dibyasakti
Eye Diseases
Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease
In active phase of thyroid eye disease some patients have obvious upper lid retraction , and sometimes exposure keratopathy .To date there is not any standard treatment for this situation .
- Trial name
- NCT00370734
- Testing
- Botulinum toxin A injection
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Graves Ophthalmopathy
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease
Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments.
- Trial name
- TED (NCT03324022)
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease, Graves Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy
- Trial name
- NCT06226545
- Testing
- LASN01
- Where
- 15 sites in United States, Spain and 1 more
- Volunteers
- 41 people
- Sponsor
- Lassen Therapeutics Inc.
Thyroid Eye Disease, Ocular Hypertension
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients.
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Trial name
- NCT01927406
- Testing
- Prostaglandin Analog, Timolol
- Where
- United States
- Sponsor
- Stanford University
Thyroid Associated Ophthalmopathy
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied.
- Trial name
- NCT03107078
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jie Shen
Graves Ophthalmopathy
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
The purpose of the present interventional study is to assess the changes in the therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.
- Trial name
- NCT05775185
- Testing
- Orbital radiotherapy
- Where
- Bulgaria
- Volunteers
- 26 people
- Sponsor
- Medical University of Sofia
Thyroid Eye Disease, Graves Ophthalmopathy
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy: A Randomized Control Trial.; The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy, focusing on…
- Trial name
- NCT06413043
- Testing
- Selenium
- Where
- India
- Volunteers
- 78 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Thyroid Associated Opthalmopathies
Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
The aim of this study is to compare the efficacy and safety of prednisone versus sub-antimicrobial dose doxycycline (50 mg/d) in the treatment of active moderate-severe Graves' Orbitopathy (GO).
- Trial name
- NCT01809444
- Where
- 6 sites in China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University
Graves' Orbitopathy, Graves' Disease
Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy
Graves' disease (GD) is the commonest cause of hyperthyroidism, characterised by anti-thyrotropin receptor autoantibodies (TRAb) persistently stimulating the thyroid gland.
- Conditions
- Graves' Orbitopathy, Graves' Disease, Graves' Ophthalmopathy, Basedow Disease
- Trial name
- MISS:GO (NCT07870161)
- Testing
- Aspiration 0
- Where
- Italy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico